Randomized trial comparing primidone initiation schedules for treating essential tremor
Identifieur interne : 004314 ( Main/Exploration ); précédent : 004313; suivant : 004315Randomized trial comparing primidone initiation schedules for treating essential tremor
Auteurs : Padraig O'Suilleabhain [États-Unis] ; Richard B. Dewey Jr. [États-Unis]Source :
- Movement Disorders [ 0885-3185 ] ; 2002-03.
Descripteurs français
- Pascal (Inist)
- Wicri :
- topic : Homme.
English descriptors
- KwdEn :
- Administration, Oral, Adult, Aged, Aged, 80 and over, Anticonvulsant, Chemotherapy, Dose-Response Relationship, Drug, Double-Blind Method, Drug Administration Schedule, Essential, Essential Tremor (diagnosis), Essential Tremor (drug therapy), Female, Human, Humans, Initiation, Low dose, Male, Middle Aged, Primidone, Primidone (administration & dosage), Primidone (adverse effects), Pyrimidine derivatives, Secondary effect, Treatment, Tremor, essential tremor, primidone initiation.
- MESH :
- chemical , administration & dosage : Primidone.
- chemical , adverse effects : Primidone.
- diagnosis : Essential Tremor.
- drug therapy : Essential Tremor.
- Administration, Oral, Adult, Aged, Aged, 80 and over, Dose-Response Relationship, Drug, Double-Blind Method, Drug Administration Schedule, Female, Humans, Male, Middle Aged.
Abstract
Early side effects are common when primidone is used to treat essential tremor, with as many as one‐third of patients failing to tolerate the tablets. Lower doses can be prescribed initially using a suspension formulation. We suspected suspension initiation would result in fewer early side effects, allow better acclimatization, and improve compliance. Forty patients with essential tremor were randomized to begin primidone treatment using either 2.5 mg doses in the suspension form or 25 mg doses in the tablet form. Doses gradually increased over 3 weeks to 150 mg/day. This was a double‐blind, double‐dummy trial. Medication cessation due to side effects was designated the primary end‐point. Four patients in the suspension group and two in the tablet group dropped out due to early side effects, resulting in a relative risk of 1.9 (95% confidence interval 0.4 to 9.2). Side effects in the first 48 hours of treatment were equally common, affecting seven subjects in each group. Treatment benefits were the same in both groups. We concluded that use of a very low initial dose and a graduated titration schedule in suspension formulation did not appear to improve primidone tolerability. If anything, compliance tended to be worse when compared with the tablet formulation, though the study was under‐powered to reject the null hypothesis of equivalence. © 2002 Movement Disorder Society.
Url:
DOI: 10.1002/mds.10083
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 001C43
- to stream Istex, to step Curation: 001C43
- to stream Istex, to step Checkpoint: 002C05
- to stream Main, to step Merge: 006319
- to stream PascalFrancis, to step Corpus: 002784
- to stream PascalFrancis, to step Curation: 000537
- to stream PascalFrancis, to step Checkpoint: 002629
- to stream Main, to step Merge: 006668
- to stream PubMed, to step Corpus: 003B17
- to stream PubMed, to step Curation: 003B17
- to stream PubMed, to step Checkpoint: 003957
- to stream Ncbi, to step Merge: 000734
- to stream Ncbi, to step Curation: 000734
- to stream Ncbi, to step Checkpoint: 000734
- to stream Main, to step Merge: 006131
- to stream Main, to step Curation: 004314
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Randomized trial comparing primidone initiation schedules for treating essential tremor</title><author><name sortKey="O Suilleabhain, Padraig" sort="O Suilleabhain, Padraig" uniqKey="O Suilleabhain P" first="Padraig" last="O'Suilleabhain">Padraig O'Suilleabhain</name></author><author><name sortKey="Dewey Jr, Richard B" sort="Dewey Jr, Richard B" uniqKey="Dewey Jr R" first="Richard B." last="Dewey Jr.">Richard B. Dewey Jr.</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:6AF1E50EEE5C23A6421501A9FBFADF8082C0B024</idno><date when="2002" year="2002">2002</date><idno type="doi">10.1002/mds.10083</idno><idno type="url">https://api.istex.fr/document/6AF1E50EEE5C23A6421501A9FBFADF8082C0B024/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">001C43</idno><idno type="wicri:Area/Istex/Curation">001C43</idno><idno type="wicri:Area/Istex/Checkpoint">002C05</idno><idno type="wicri:doubleKey">0885-3185:2002:O Suilleabhain P:randomized:trial:comparing</idno><idno type="wicri:Area/Main/Merge">006319</idno><idno type="wicri:source">INIST</idno><idno type="RBID">Pascal:02-0311360</idno><idno type="wicri:Area/PascalFrancis/Corpus">002784</idno><idno type="wicri:Area/PascalFrancis/Curation">000537</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">002629</idno><idno type="wicri:doubleKey">0885-3185:2002:O Suilleabhain P:randomized:trial:comparing</idno><idno type="wicri:Area/Main/Merge">006668</idno><idno type="wicri:source">PubMed</idno><idno type="RBID">pubmed:11921128</idno><idno type="wicri:Area/PubMed/Corpus">003B17</idno><idno type="wicri:Area/PubMed/Curation">003B17</idno><idno type="wicri:Area/PubMed/Checkpoint">003957</idno><idno type="wicri:Area/Ncbi/Merge">000734</idno><idno type="wicri:Area/Ncbi/Curation">000734</idno><idno type="wicri:Area/Ncbi/Checkpoint">000734</idno><idno type="wicri:doubleKey">0885-3185:2002:O Suilleabhain P:randomized:trial:comparing</idno><idno type="wicri:Area/Main/Merge">006131</idno><idno type="wicri:Area/Main/Curation">004314</idno><idno type="wicri:Area/Main/Exploration">004314</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Randomized trial comparing primidone initiation schedules for treating essential tremor</title><author><name sortKey="O Suilleabhain, Padraig" sort="O Suilleabhain, Padraig" uniqKey="O Suilleabhain P" first="Padraig" last="O'Suilleabhain">Padraig O'Suilleabhain</name><affiliation wicri:level="1"><country wicri:rule="url">États-Unis</country></affiliation><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, University of Texas Southwestern Medical Center, Dallas, Texas</wicri:regionArea><placeName><region type="state">Texas</region></placeName></affiliation></author><author><name sortKey="Dewey Jr, Richard B" sort="Dewey Jr, Richard B" uniqKey="Dewey Jr R" first="Richard B." last="Dewey Jr.">Richard B. Dewey Jr.</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, University of Texas Southwestern Medical Center, Dallas, Texas</wicri:regionArea><placeName><region type="state">Texas</region></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>New York</pubPlace><date type="published" when="2002-03">2002-03</date><biblScope unit="vol">17</biblScope><biblScope unit="issue">2</biblScope><biblScope unit="page" from="382">382</biblScope><biblScope unit="page" to="386">386</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">6AF1E50EEE5C23A6421501A9FBFADF8082C0B024</idno><idno type="DOI">10.1002/mds.10083</idno><idno type="ArticleID">MDS10083</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Administration, Oral</term><term>Adult</term><term>Aged</term><term>Aged, 80 and over</term><term>Anticonvulsant</term><term>Chemotherapy</term><term>Dose-Response Relationship, Drug</term><term>Double-Blind Method</term><term>Drug Administration Schedule</term><term>Essential</term><term>Essential Tremor (diagnosis)</term><term>Essential Tremor (drug therapy)</term><term>Female</term><term>Human</term><term>Humans</term><term>Initiation</term><term>Low dose</term><term>Male</term><term>Middle Aged</term><term>Primidone</term><term>Primidone (administration & dosage)</term><term>Primidone (adverse effects)</term><term>Pyrimidine derivatives</term><term>Secondary effect</term><term>Treatment</term><term>Tremor</term><term>essential tremor</term><term>primidone initiation</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Primidone</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Primidone</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Essential Tremor</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Essential Tremor</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Administration, Oral</term><term>Adult</term><term>Aged</term><term>Aged, 80 and over</term><term>Dose-Response Relationship, Drug</term><term>Double-Blind Method</term><term>Drug Administration Schedule</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Anticonvulsivant</term><term>Chimiothérapie</term><term>Dose faible</term><term>Effet secondaire</term><term>Essentiel</term><term>Homme</term><term>Initiation</term><term>Primidone</term><term>Pyrimidine dérivé</term><term>Traitement</term><term>Tremblement</term></keywords><keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Early side effects are common when primidone is used to treat essential tremor, with as many as one‐third of patients failing to tolerate the tablets. Lower doses can be prescribed initially using a suspension formulation. We suspected suspension initiation would result in fewer early side effects, allow better acclimatization, and improve compliance. Forty patients with essential tremor were randomized to begin primidone treatment using either 2.5 mg doses in the suspension form or 25 mg doses in the tablet form. Doses gradually increased over 3 weeks to 150 mg/day. This was a double‐blind, double‐dummy trial. Medication cessation due to side effects was designated the primary end‐point. Four patients in the suspension group and two in the tablet group dropped out due to early side effects, resulting in a relative risk of 1.9 (95% confidence interval 0.4 to 9.2). Side effects in the first 48 hours of treatment were equally common, affecting seven subjects in each group. Treatment benefits were the same in both groups. We concluded that use of a very low initial dose and a graduated titration schedule in suspension formulation did not appear to improve primidone tolerability. If anything, compliance tended to be worse when compared with the tablet formulation, though the study was under‐powered to reject the null hypothesis of equivalence. © 2002 Movement Disorder Society.</div></front></TEI><affiliations><list><country><li>États-Unis</li></country><region><li>Texas</li></region></list><tree><country name="États-Unis"><noRegion><name sortKey="O Suilleabhain, Padraig" sort="O Suilleabhain, Padraig" uniqKey="O Suilleabhain P" first="Padraig" last="O'Suilleabhain">Padraig O'Suilleabhain</name></noRegion><name sortKey="Dewey Jr, Richard B" sort="Dewey Jr, Richard B" uniqKey="Dewey Jr R" first="Richard B." last="Dewey Jr.">Richard B. Dewey Jr.</name><name sortKey="O Suilleabhain, Padraig" sort="O Suilleabhain, Padraig" uniqKey="O Suilleabhain P" first="Padraig" last="O'Suilleabhain">Padraig O'Suilleabhain</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004314 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 004314 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:6AF1E50EEE5C23A6421501A9FBFADF8082C0B024
|texte= Randomized trial comparing primidone initiation schedules for treating essential tremor
}}
| This area was generated with Dilib version V0.6.23. |  |